Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1819916

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1819916

Pharmacogenomics Market Report by Technology, Application, End User, and Region 2025-2033

PUBLISHED:
PAGES: 141 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 2999
PDF & Excel (5 User License)
USD 3999
PDF & Excel (Corporate License)
USD 4999

Add to Cart

The global pharmacogenomics market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 17.0 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033.

Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.

Pharmacogenomics Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Technology:

  • Polymerase Chain Reaction
  • Microarray
  • DNA Sequencing
  • Mass Spectrometry
  • Electrophoresis
  • Others

Breakup by Application:

  • Oncology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Psychiatry
  • Pain Management
  • Others

Breakup by End User:

  • Hospitals and Clinics
  • Academic and Research Institutes

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.How big is the pharmacogenomics market?
  • 2.What is the future outlook of pharmacogenomics market?
  • 3.What are the key factors driving the pharmacogenomics market?
  • 4.Which are the leading companies in the global pharmacogenomics market?
Product Code: SR112025A4396

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacogenomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Polymerase Chain Reaction
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Microarray
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Sequencing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mass Spectrometry
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Electrophoresis
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Infectious Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cardiovascular Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Neurological Diseases
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Psychiatry
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Pain Management
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Academic and Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Becton Dickinson and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Rad Laboratories Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GlaxoSmithKline plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Illumina Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Johnson & Johnson
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Myriad Genetics Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Qiagen N.V.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Thermo Fisher Scientific Inc
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis
Product Code: SR112025A4396

List of Figures

  • Figure 1: Global: Pharmacogenomics Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacogenomics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Pharmacogenomics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Pharmacogenomics Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Pharmacogenomics Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Pharmacogenomics Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Pharmacogenomics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Pharmacogenomics (Polymerase Chain Reaction) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Pharmacogenomics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Pharmacogenomics (Microarray) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Pharmacogenomics (Microarray) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Pharmacogenomics (DNA Sequencing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Pharmacogenomics (DNA Sequencing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Pharmacogenomics (Mass Spectrometry) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Pharmacogenomics (Mass Spectrometry) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Pharmacogenomics (Electrophoresis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Pharmacogenomics (Electrophoresis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Pharmacogenomics (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Pharmacogenomics (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Pharmacogenomics (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Pharmacogenomics (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Pharmacogenomics (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Pharmacogenomics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Pharmacogenomics (Cardiovascular Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Pharmacogenomics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Pharmacogenomics (Neurological Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Pharmacogenomics (Neurological Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Pharmacogenomics (Psychiatry) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Pharmacogenomics (Psychiatry) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Pharmacogenomics (Pain Management) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Pharmacogenomics (Pain Management) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Pharmacogenomics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Pharmacogenomics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Pharmacogenomics (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Pharmacogenomics (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Pharmacogenomics (Academic and Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Pharmacogenomics (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: North America: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: North America: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: United States: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: United States: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Canada: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Canada: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Asia-Pacific: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Asia-Pacific: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: China: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: China: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Japan: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Japan: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: India: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: India: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: South Korea: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: South Korea: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Australia: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Australia: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Indonesia: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Indonesia: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Europe: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Europe: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Germany: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Germany: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: France: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: France: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: United Kingdom: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: United Kingdom: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Italy: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Italy: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Spain: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Spain: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Russia: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Russia: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Latin America: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Latin America: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Brazil: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Brazil: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Mexico: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Mexico: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Others: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Others: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Middle East and Africa: Pharmacogenomics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Middle East and Africa: Pharmacogenomics Market: Breakup by Country (in %), 2024
  • Figure 86: Middle East and Africa: Pharmacogenomics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Global: Pharmacogenomics Industry: SWOT Analysis
  • Figure 88: Global: Pharmacogenomics Industry: Value Chain Analysis
  • Figure 89: Global: Pharmacogenomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacogenomics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Pharmacogenomics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Pharmacogenomics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Pharmacogenomics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Pharmacogenomics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Pharmacogenomics Market: Competitive Structure
  • Table 7: Global: Pharmacogenomics Market: Key Playe
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!